Johnson & Johnson (NYSE: JNJ) has been working on its pipeline for a while, and plans on continuing to do so. In an effort to strengthen its portfolio, this pharmaceutical giant released its plan to file for more products, which each stand to make a substantial amount of revenue.

The total pharmaceutical market reached the $1 trillion mark in 2014. Nearly 40% of the growth came from specialty medicines, which included oncology, autoimmune, respiratory and anti-viral medications.

Looking ahead, the total global branded pharmaceuticals market is expected to grow at a compound annual operational growth rate of roughly 3% from 2014 to 2019, according to IMS Health. Among the top 10 global pharmaceutical companies, IMS Health also reports that the Pharmaceutical segment of Johnson & Johnson was among the fastest growing in the United States, Europe and Japan in 2014. This segment had sales of $32.3 billion, representing an operational increase of 16.5% compared to 2013.

To continue this growth, Johnson & Johnson announced plans to file over 10 new products for approval, as well as 40 line extensions of existing and new medicines. The kicker is that each one of these candidates has the potential to generate $1 billion in revenue each.

ALSO READ: 5 Top Potential Biotech Buyout Candidates

Johnson & Johnson has launched 14 new products since 2009, seven of which already exceed or are on track to achieve sales in excess of $1 billion during 2015. Ultimately this has been a strong driver for growth within the company and according to Joaquin Duato, Worldwide Chairman of Pharmaceuticals at Johnson & Johnson:

In the past two years, our performance and growth rates have been industry-leading, and we look forward to continuing to drive above-industry growth with our current in-market portfolio and next wave of medicines. We are working with our partners to advance the innovative products in our pipeline and to deliver significant benefits to patients.

The company focuses its portfolio on five core therapeutic areas: Immunology, Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology. The combined strength of Johnson & Johnson’s in-market portfolio and robust near-term pipeline provides the momentum to sustain above-industry compound annual growth through 2019.

Johnson & Johnson named its indications:

Late-stage products expected to drive growth in the next several years, following regulatory approvals, include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer; esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C.4 In addition, daratumumab and esketamine have both received Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA). Janssen is also announcing today that it plans to submit a Biologic Licensing Application to the FDA and a Marketing Authorization Application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase 2 data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.

ALSO READ: The 5 Winners and Losers From ASCO Presentations

Shares of Johnson & Johnson were up 0.3% at $104.24 Wednesday morning. The stock has a consensus analyst price target of $109.02 and a 52-week trading range of $95.10 to $109.49.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.